| 109.51 -6.35 (-5.48%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 153.28 | 1-year : | 179.04 |
| Resists | First : | 131.24 | Second : | 153.28 |
| Pivot price | 114.23 |
|||
| Supports | First : | 103.79 | Second : | 86.83 |
| MAs | MA(5) : | 110.15 |
MA(20) : | 117.26 |
| MA(100) : | 89.67  |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 27.8 |
D(3) : | 23.4 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 131.24 | Low : | 35.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MANE ] has closed above bottom band by 30.7%. Bollinger Bands are 10.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 118 - 118.6 | 118.6 - 119.06 |
| Low: | 107.94 - 108.54 | 108.54 - 109 |
| Close: | 108.57 - 109.57 | 109.57 - 110.33 |
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Wed, 15 Jul 2026
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTrade
Wed, 15 Jul 2026
Veradermics reports phase 2 hair loss trial results - Investing.com
Wed, 15 Jul 2026
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - Yahoo Finance
Wed, 15 Jul 2026
Veradermics jumps after data for hair loss drug (MANE:NYSE) - Seeking Alpha
Wed, 15 Jul 2026
Up to 90% of women reported better hair coverage by Month 6 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 79.8 (%) |
| Shares Short | 2,490 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -2.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -41.33 |
| PEG Ratio | 0 |
| Price to Book value | 10.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -57.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|